A PHASE I TRIAL OF RADIOIMMUNOTHERAPY (Y-90 CT8466), GEMCITABINE AND HEPATIC

放射免疫治疗 (Y-90 CT8466)、吉西他滨和肝脏的 I 期试验

• 批准号: 7982065
• 负责人: JEFFREY Y WONG
• 金额: $ 0.7万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982065
• 关键词: 90Y; Ablation; Adjuvant Therapy; Biodistribution; Cancer Patient; Clinical Research; Colorectal Cancer; Computer Retrieval of Information on Scientific Projects Database; Dose; Excision; Feasibility Studies; Funding; Grant; Hepatic; Image; Indium-111; Infusion procedures; Institution; Intravenous; Maximum Tolerated Dose; Metabolism; Metastatic Neoplasm to the Liver; Nuclear; Operative Surgical Procedures; Organ; Phase I Clinical Trials; Proteomics; Radiation; Radioimmunotherapy; Research; Research Personnel; Resources; Source; Toxic effect; Tumor Debulking; United States National Institutes of Health; gemcitabine; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives are to determine the maximum tolerated dose (MTD) and associated toxicities of concurrent hepatic arterial infusion (HAI) fluorodeoxypyrimide (FUdR) and intravenous gemcitabine combined with intravenous Yttrium-90 chimeric T84.66 in colorectal cancer patients after hepatic resection or maximum surgical debulking (to <3cm) of liver metastases; to study the feasibility and toxicities of such adjuvant therapy following resection and/or ablation of liver metastases; to evaluate the biodistribution, clearance and metabolism of Yttrium-90 and Indium-111 chimeric T84.66 administered intravenously; to estimate radiation doses to whole body, normal organs and tumor through serial nuclear imaging; to correlate proteomic profiles pre and post-therapy with toxicities and anti-tumor effects.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这些目的是确定最大耐受剂量（MTD）和相关的肝动脉输注（HAI）氟脱氧氧化酰亚胺（FUDR）和吉西替滨静脉内静脉内httrium yttrium-90 Chimeric T84.66结合抗术后抗形性癌症或最大值的heptical corgivical t84.66的evectical t84.66 e术<memectical-n.66转移；研究切除和/或消融肝转移后这种辅助治疗的可行性和毒性；为了评估Yttrium-90和indium-111 Chimeric T84.66的生物分布，清除和代谢，静脉注射；为了估计整个身体的辐射剂量，通过串行核成像进行正常的器官和肿瘤；将蛋白质组织前后疗法与毒性和抗肿瘤作用相关联。